[go: up one dir, main page]

WO2007137387A1 - Complément diététique d'efficacité améliorée au moment de la consommation - Google Patents

Complément diététique d'efficacité améliorée au moment de la consommation Download PDF

Info

Publication number
WO2007137387A1
WO2007137387A1 PCT/CA2006/000874 CA2006000874W WO2007137387A1 WO 2007137387 A1 WO2007137387 A1 WO 2007137387A1 CA 2006000874 W CA2006000874 W CA 2006000874W WO 2007137387 A1 WO2007137387 A1 WO 2007137387A1
Authority
WO
WIPO (PCT)
Prior art keywords
creatine
dietary supplement
compartment
ingredient
aqueous medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2006/000874
Other languages
English (en)
Inventor
Marvin A. Heuer
Shan Chaudhuri
James D. Ramsbottom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New Cell Formulations Ltd
Original Assignee
New Cell Formulations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Cell Formulations Ltd filed Critical New Cell Formulations Ltd
Priority to PCT/CA2006/000874 priority Critical patent/WO2007137387A1/fr
Publication of WO2007137387A1 publication Critical patent/WO2007137387A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2093—Containers having several compartments for products to be mixed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives

Definitions

  • the present invention relates to a dietary supplement, e.g., ready-to- drink supplements that include ingredients, e.g., creatine and derivatives thereof, which may be unstable if dissolved in an aqueous solution significantly before the dietary supplement is to be consumed.
  • ingredients e.g., creatine and derivatives thereof
  • the present invention may improve the efficacy of the ingredient at the time of consumption.
  • a dietary supplement that includes a container having a first compartment and a second compartment.
  • the first compartment includes an aqueous medium.
  • the second compartment includes an ingredient that is stable when stored within the second compartment.
  • the container is configured such that a user may selectively cause the first and second compartments to be in communication with each other such that the ingredient of the second compartment is mixed with the aqueous medium of the first compartment.
  • the ingredient which may be creatine or a derivative thereof, is less stable after being mixed with the aqueous medium of the first compartment.
  • a dietary supplement that is provided in a container.
  • a first compartment of the container includes an aqueous medium.
  • a second compartment of the container includes at least one ingredient.
  • the ingredient may be more stable when stored separately from the aqueous solution as compared to when dissolved in the aqueous solution.
  • the first and second compartments are not in communication with each other.
  • the first and second compartments are in communication with each other and the ingredient is mixed with the aqueous medium.
  • an ingredient of a dietary supplement may be provided to a user is by suspending or dissolving the ingredient in an aqueous solution. While some dietary supplements may provide an ingredient pre- mixed in the aqueous solution, there are some ingredients (for example, creatine and others discussed in greater detail below) for which the suspension or dissolution of the ingredient within a solution for longer than a given period of time may undesirably alter, e.g., degrade or otherwise transform, the ingredient's molecular make-up and thus adversely effect the ingredient's function.
  • ingredients for example, creatine and others discussed in greater detail below
  • the present invention may improve the stability and/or efficacy of certain active ingredients by storing such ingredients in separate compartments of a single container.
  • the separate compartments provide, prior to the consumption of the supplement, a physical barrier between the components of the dietary supplement, e.g., between the aqueous solution and the ingredient that may exhibit compromised stability and/or efficacy upon being, or within a given amount of time after being, dissolved in the aqueous solution.
  • a user may selectively cause the contents of the separate compartments to mix. For example, the user may deform or otherwise manipulate the two compartments such that the ingredient stored in a first compartment is mixed with the aqueous solution in the second compartment. Since the user may perform this step, e.g., mixing the ingredient stored in the first compartment with the aqueous solution in the second compartment, at the time that the dietary supplement is to be consumed, any instability and/or inefficacy which may have resulted from the ingredient being dissolved in an aqueous solution for longer than a given period of time may be avoided.
  • отно ⁇ ески ⁇ иили от ⁇ ество may include creatine also know as (alpha-methyl) guandino-acetic acid.
  • Creatine is one of the basic molecules involved with energy storage, particularly in fast twitch glycolytic fibres. Creatine loading is known to increase the creatine stored within muscle tissue. Moreover, creatine is able to reversibly bind phosphate. Therefore, if more creatine is present within a muscle tissue, there is more stored and donatable phosphate within the muscle tissue. When a muscle undergoes a contraction, it employs adenosine triphosphate (ATP) as an energy source.
  • ATP adenosine triphosphate
  • a phosphate group is cleaved from ATP leaving the molecule adenosine diphosphate (ADP), which is devoid of energetic properties with respect to muscular contraction (Tortora GJ, Grabowski SR. Principles of Anatomy and Physiology. 8 th Ed. Addison Wesley Longman, Inc. Don Mills, ON. 1996).
  • Creatine is able to pick-up a phosphate and reversibly bind it; forming Phospho-creatine.
  • Phospho-creatine ultimately donates a phosphate to ADP, thus rendering ATP, which is able to be used in a subsequent muscular contraction immediately following intense muscle effort and provides enough energy for 15 seconds of maximal contraction.
  • creatine loading aids in the regeneration of ATP, leading to an increase in muscular output ability.
  • Creatine converts to creatinine via an irreversible, pH-dependent, non- enzymatic reaction in aqueous medium.
  • Aqueous and alkaline solutions contain a mixture of creatine and creatinine. In acidic solutions, 100% of creatine is converted to creatinine.
  • creatine plays an important role in storing high energy phosphate for muscle use, creatinine is inactive and is excreted by the kidneys (Mesa JL, Ruiz JR, Gonzalez-Gross MM, Gutierrez Sainz A, Castillo Garzon MJ, Oral creatine supplementation and skeletal muscle metabolism in physical exercise. Sports Med. 2002;32(14):903-44. Review.).
  • Creatine is also known as 2-(carbamimidoyl-methyl-amino) acetic acid, N-(aminoiminomethyl)-N-methylglycine, N-amidinosarcosine, (alpha- methylguanido) acetic acid, N-methyl-N-guanylgliycine and methylglycocyamine.
  • Creatine as used herein may refer to creatine in any of its known forms, e.g., salts and/or esters thereof.
  • creatine in its various forms include but are not limited to creatine monohydrate, creatine alpha ketoglutarate, creatine ethyl ester HCI, tricreatine hydroxycitrate, creatine citrate, creatine pyruvate, creatine pyroglutamate, dicreatine malate, creatine anhydrous, creatine taurinate, and creatine methyl ester.
  • Tricreatine hydroxycitrate is another example of a creatine derivative which may be unstable in an aqueous medium. It is formed in an anionic- cationic reaction whereby three moles of creatine are bound to one mole of hydroxycitric acid.
  • the present invention in accordance with various embodiments thereof, involves a dietary supplement that is disposed in a container that has at least two compartments.
  • the ingredient may be maintained in a first compartment of the container until a user selectively causes, e.g., immediately prior to consumption, the ingredient to be mixed with an aqueous solution stored in a second compartment of the container.
  • U.S. Patent No. 2,562,402 discloses a two compartment container wherein the outer container is comprised of a flexible material which upon squeezing increases the internal pressure.
  • the inner container or capsule is pressure-sensitive and upon an increase in the internal pressure of the outer container, the inner capsule ruptures and its contents are mixed with the contents of the outer container.
  • U.S. Patent No. 2,753,990 discloses a glass container having large and small-sized, separate compartments for the storage of the first and second liquids in the separate storage compartments. When the large compartment is opened, thus resulting in a drop in pressure below that of the small compartment leads to the opening of a valve in the wall separating the two compartments allowing for the mixing of the liquids in the two compartments.
  • U.S. Patent No. 4,627,986 discloses a container for the storage of a pressurized fluid, having a separate compartment therein for the segregated storage of a second material. The mechanism is arranged such that it is sensitive to the rapid drop in pressure upon the opening of the container and that the contents of the segregated container are released into the fluid of the first container.
  • U.S. Patent No. 6,620,444 discloses a two compartment container under pressure wherein the inner compartment opens in response to pressure change upon the opening of the outer compartment. The contents of the inner container are thus released and mixed with the contents of the outer container immediately prior to consumption.
  • Examples 1 to 4 below illustrate some of the dietary supplements that may advantageously employ such containers.
  • these dietary supplements include active ingredients that may irreversibly convert to inactive forms of the ingredient were the ingredients to be dissolved in the respective aqueous solution greater than a given period of time prior to a user consuming the dietary supplement.
  • the stability and/or efficacy of the ingredients may be increased by preventing the active molecules from dissolving or being suspended in the aqueous solution until a predetermined time period, e.g., immediately, prior to consumption.
  • a dietary supplement is contained within a container comprising two compartments.
  • a solute mixture of granular anhydrous creatine (2.5000 g), calcium salt of ketoisocaproic acid (0.0500 g), and trometamol salt of alpha lipoic acid (0.1000 g) is contained within a container comprising two compartments.
  • a solute mixture of granular anhydrous creatine (2.5000 g), calcium salt of ketoisocaproic acid (0.0500 g), and trometamol salt of alpha lipoic acid (0.1000 g) is contained within a second compartment.
  • a solvent is contained.
  • the contents of the first compartment are emptied, e.g., automatically, into the second compartment such that the solutes contained within the first compartment are combined with the solvent in the second compartment to form a consumable solution.
  • a dietary supplement is contained within a container comprising two compartments. Within a first compartment, a solute mixture of creatine citrate
  • trometamol salt of alpha lipoic acid 0.0510 g
  • creatine alpha ketoglutarate 0.0010 g
  • creatine ethyl ester HCI 0.0010 g
  • creatine methyl ester 0.0010 g
  • dicreatine malate 0.0010 g
  • a dietary supplement is contained within a container comprising two compartments.
  • a solvent is contained within a second compartment.
  • the contents of the first compartment are emptied, e.g., automatically, into the second compartment such that the solutes contained within the first compartment are combined with the solvent in the second compartment to form a consumable solution.
  • Example 4 A dietary supplement is contained within a container comprising two compartments. Within a first compartment, a solute mixture comprising at least tricreatine hydroxycitric acid or a derivative thereof is contained. Within a second compartment, a solvent is contained. At the time of opening the two- compartment container, the contents of the first compartment are emptied, e.g., automatically, into the second compartment such that the solutes contained within the first compartment are combined with the solvent in the second compartment to form a consumable solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un complément diététique conditionné dans un récipient, le récipient comprenant un premier compartiment et un second compartiment. Le premier compartiment contient un milieu aqueux. Le second compartiment contient le complément diététique, qui est stable lorsqu'il est stocké à l'intérieur du second compartiment. Le récipient est conçu de façon qu'un utilisateur peut sélectivement provoquer la communication entre les premier et second compartiments pour que le complément diététique du second compartiment soit mélangé avec le milieu aqueux du premier compartiment. Le complément diététique, qui peut être la créatine ou l'un de ses dérivés, est moins stable après avoir été mélangé avec le milieu aqueux du premier compartiment.
PCT/CA2006/000874 2006-05-30 2006-05-30 Complément diététique d'efficacité améliorée au moment de la consommation Ceased WO2007137387A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CA2006/000874 WO2007137387A1 (fr) 2006-05-30 2006-05-30 Complément diététique d'efficacité améliorée au moment de la consommation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2006/000874 WO2007137387A1 (fr) 2006-05-30 2006-05-30 Complément diététique d'efficacité améliorée au moment de la consommation

Publications (1)

Publication Number Publication Date
WO2007137387A1 true WO2007137387A1 (fr) 2007-12-06

Family

ID=38778039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2006/000874 Ceased WO2007137387A1 (fr) 2006-05-30 2006-05-30 Complément diététique d'efficacité améliorée au moment de la consommation

Country Status (1)

Country Link
WO (1) WO2007137387A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2562402A (en) * 1949-04-05 1951-07-31 Food Res Lab Inc Dispensing unit for therapeutic agents
US2753990A (en) * 1953-07-02 1956-07-10 Chalfin Philip Container
US4627986A (en) * 1982-01-04 1986-12-09 General Foods Corporation Pressurized container providing for the separate storage of a plurality of materials
US6620444B1 (en) * 1998-04-22 2003-09-16 Schmalbach-Lubeca Ag Two-compartment container for and method of admixing a flavour to a beverage

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2562402A (en) * 1949-04-05 1951-07-31 Food Res Lab Inc Dispensing unit for therapeutic agents
US2753990A (en) * 1953-07-02 1956-07-10 Chalfin Philip Container
US4627986A (en) * 1982-01-04 1986-12-09 General Foods Corporation Pressurized container providing for the separate storage of a plurality of materials
US6620444B1 (en) * 1998-04-22 2003-09-16 Schmalbach-Lubeca Ag Two-compartment container for and method of admixing a flavour to a beverage

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Retrieved from the Internet <URL:http://www.muscle-shop.co.uk/products/asp/prodID/203041/af/page.htm> *

Similar Documents

Publication Publication Date Title
US12448357B1 (en) Amino acid compositions
US5925378A (en) Method for enhancing delivery and uniformity of concentration of cellular creatine
US8048921B2 (en) Amino acid compounds
CA2914514C (fr) Procede pour produire des microcapsules comprenant un composant actif encapsule, protege et stabilise dans une enveloppe proteique.
JP2006510711A5 (fr)
KR0143232B1 (ko) 철 공급용 제제, 비타민 공급용 제제 및 발포 제제의 안정화 방법
US10646508B1 (en) Method of safely administering nitrate dietary supplements and compositions
US7786073B2 (en) Container for dietary supplement having improved efficacy at time of consumption
CA2548695C (fr) Complement alimentaire ayant une efficacite accrue lors de sa consommation
WO2007137387A1 (fr) Complément diététique d&#39;efficacité améliorée au moment de la consommation
US10435356B1 (en) Amino acid compositions
US20020131987A1 (en) Method for enhancing stable cellular creatine concentration
JP2002531392A (ja) 水の存在下で可溶で、乾燥状態でマイヤール反応を防止する乾燥組成物の製造及び使用
Raghavendra Rao et al. l‐[3H] Nitroarginine and l‐[3H] Arginine Uptake into Rat Cerebellar Synaptosomes: Kinetics and Pharmacology
US10426792B1 (en) Amino acid compositions
US10426750B1 (en) Amino acid supplement formulations
US20080153897A1 (en) Creatine pyroglutamic acid salts and methods for their production and use in individuals
WO2012034201A2 (fr) Composition de complément alimentaire contenant de la créatine, procédé pour sa préparation et forme pharmaceutique de complément alimentaire
AU4954199A (en) Method for enhancing stable cellular creatine concentration
EP2349249B1 (fr) Composition synergique pour rétablir et réduire une lésion ischémique bénigne
JP5294194B2 (ja) 脳血管性認知症の治療薬
WO2009079739A1 (fr) Utilisation de sel d&#39;acide pyroglutamique de créatine pour favoriser une meilleure santé des neurones
CA2612550A1 (fr) Pyroglutamates de creatine et methodes pour leur production et leur utilisation chez des personnes
US20250163000A1 (en) Amino acid compositions
Raj et al. GLUTAMINE KINETICS AND PROTEIN TURNOVER IN END-STAGE RENAL

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06752728

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 12-03-2009)

122 Ep: pct application non-entry in european phase

Ref document number: 06752728

Country of ref document: EP

Kind code of ref document: A1